WEGOVY FLEXTOUCH 2.4MG INJ

Distributor inventory | Injection

Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, type 2 diabetes); used along with reduced-calorie diet and increased physical activity.

Semaglutide is a GLP-1 receptor agonist that increases satiety and reduces hunger by acting on appetite-regulating centers in the brain. It also slows gastric emptying and can improve glucose control, leading to reduced calorie intake and weight loss.

Subcutaneous injection once weekly on the same day each week, at any time of day, with or without meals. Inject into abdomen, thigh, or upper arm; rotate injection sites. Use only after completing dose escalation and as prescribed; do not share the pen/needles; follow pen instructions for priming and dose delivery.

Nausea, vomiting, diarrhoea, constipation, abdominal pain, dyspepsia, decreased appetite, headache, fatigue, dizziness, injection site reactions

Prescription-only. Risk of pancreatitis (seek care for severe persistent abdominal pain); gallbladder disease (cholelithiasis/cholecystitis) possible. May cause dehydration and worsen kidney function due to GI side effects—maintain fluids. Contraindicated/avoid in patients with personal/family history of medullary thyroid carcinoma or MEN2; discontinue if thyroid mass/hoarseness develops. Monitor for hypoglycaemia when used with insulin or sulfonylureas. Not recommended in severe gastrointestinal disease (e.g., gastroparesis). Stop before major surgery if advised; monitor for diabetic retinopathy worsening in patients with diabetes. Do not use for type 1 diabetes or for diabetic ketoacidosis.